AIMS/HYPOTHESIS: Optimising islet culture conditions may be one strategy for reducing islet loss prior to, and immediately after, islet transplantation. Liver X receptor (LXR) agonism has previously been shown to increase insulin release from pancreatic islets and reduce inflammation in leucocytes. Our aim was to investigate whether the synthetic LXR agonist GW3965 could modulate the inflammatory status of human pancreatic islets. METHODS: Levels of pro-inflammatory cytokines and tissue factor in isolated human islets were determined by TaqMan low density array and/or real-time quantitative RT-PCR (mRNA levels) and enzyme immunoassay (EIA) (protein levels). Islet viability was measured using intracellular ATP content, ADP/ATP ratio, mitochondrial dehydrogenase activity (XTT assay) and insulin secretion in a dynamic glucose-challenge model. Apoptosis was determined by EIA measurement of histone-DNA complexes present in cytoplasm and by assaying caspase-3/-7 activity. RESULTS: Treatment of LPS-stimulated human islets with the synthetic LXR agonist GW3965 (1 micromol/l) for 24 h reduced mRNA and protein levels of selected pro-inflammatory cytokines (IL-8, monocyte chemotactic protein-1 and tissue factor). Moreover, GW3965 had no adverse effect on insulin secretion, islet viability or apoptosis. No excess of lipid accumulation could be detected with the dosage and exposure time used. CONCLUSIONS/ INTERPRETATION: LXR activation suppresses inflammation in human islets in vitro without adverse effects on islet viability. Short-term moderate activation of LXR prior to islet transplantation may represent a possible strategy for improving post-transplant islet survival.
AIMS/HYPOTHESIS: Optimising islet culture conditions may be one strategy for reducing islet loss prior to, and immediately after, islet transplantation. Liver X receptor (LXR) agonism has previously been shown to increase insulin release from pancreatic islets and reduce inflammation in leucocytes. Our aim was to investigate whether the synthetic LXR agonist GW3965 could modulate the inflammatory status of humanpancreatic islets. METHODS: Levels of pro-inflammatory cytokines and tissue factor in isolated human islets were determined by TaqMan low density array and/or real-time quantitative RT-PCR (mRNA levels) and enzyme immunoassay (EIA) (protein levels). Islet viability was measured using intracellular ATP content, ADP/ATP ratio, mitochondrial dehydrogenase activity (XTT assay) and insulin secretion in a dynamic glucose-challenge model. Apoptosis was determined by EIA measurement of histone-DNA complexes present in cytoplasm and by assaying caspase-3/-7 activity. RESULTS: Treatment of LPS-stimulated human islets with the synthetic LXR agonist GW3965 (1 micromol/l) for 24 h reduced mRNA and protein levels of selected pro-inflammatory cytokines (IL-8, monocyte chemotactic protein-1 and tissue factor). Moreover, GW3965 had no adverse effect on insulin secretion, islet viability or apoptosis. No excess of lipid accumulation could be detected with the dosage and exposure time used. CONCLUSIONS/ INTERPRETATION: LXR activation suppresses inflammation in human islets in vitro without adverse effects on islet viability. Short-term moderate activation of LXR prior to islet transplantation may represent a possible strategy for improving post-transplant islet survival.
Authors: A M James Shapiro; Camillo Ricordi; Bernhard J Hering; Hugh Auchincloss; Robert Lindblad; R Paul Robertson; Antonio Secchi; Mathias D Brendel; Thierry Berney; Daniel C Brennan; Enrico Cagliero; Rodolfo Alejandro; Edmond A Ryan; Barbara DiMercurio; Philippe Morel; Kenneth S Polonsky; Jo-Anna Reems; Reinhard G Bretzel; Federico Bertuzzi; Tatiana Froud; Raja Kandaswamy; David E R Sutherland; George Eisenbarth; Miriam Segal; Jutta Preiksaitis; Gregory S Korbutt; Franca B Barton; Lisa Viviano; Vicki Seyfert-Margolis; Jeffrey Bluestone; Jonathan R T Lakey Journal: N Engl J Med Date: 2006-09-28 Impact factor: 91.245
Authors: Olle Korsgren; B Nilsson; C Berne; M Felldin; A Foss; R Kallen; T Lundgren; K Salmela; A Tibell; G Tufveson Journal: Transplantation Date: 2005-05-27 Impact factor: 4.939
Authors: Juan L Contreras; Christopher Eckstein; Cheryl A Smyth; Marty T Sellers; Mario Vilatoba; Guadalupe Bilbao; Firoz G Rahemtulla; Carlton J Young; J Anthony Thompson; Irshad H Chaudry; Devin E Eckhoff Journal: Diabetes Date: 2003-12 Impact factor: 9.461
Authors: David R Riddell; Hua Zhou; Thomas A Comery; Evguenia Kouranova; C Frederick Lo; Helen K Warwick; Robert H Ring; Yolanda Kirksey; Suzan Aschmies; Jane Xu; Katie Kubek; Warren D Hirst; Catherine Gonzales; Yi Chen; Erin Murphy; Sarah Leonard; Dmytro Vasylyev; Aram Oganesian; Robert L Martone; Menelas N Pangalos; Peter H Reinhart; J Steve Jacobsen Journal: Mol Cell Neurosci Date: 2007-01-25 Impact factor: 4.314
Authors: Michelle N Bradley; Cynthia Hong; Mingyi Chen; Sean B Joseph; Damien C Wilpitz; Xuping Wang; Aldons J Lusis; Allan Collins; Willa A Hseuh; Jon L Collins; Rajendra K Tangirala; Peter Tontonoz Journal: J Clin Invest Date: 2007-08 Impact factor: 14.808
Authors: Elin Hall; Petr Volkov; Tasnim Dayeh; Karl Bacos; Tina Rönn; Marloes Dekker Nitert; Charlotte Ling Journal: BMC Med Date: 2014-06-23 Impact factor: 8.775
Authors: Takeshi Ogihara; Jen-Chieh Chuang; George L Vestermark; James C Garmey; Robert J Ketchum; Xiaolun Huang; Kenneth L Brayman; Michael O Thorner; Joyce J Repa; Raghavendra G Mirmira; Carmella Evans-Molina Journal: J Biol Chem Date: 2009-12-11 Impact factor: 5.157